Net profit of Kwality Pharmaceuticals rose 66.71% to Rs 14.12 crore in the quarter ended September 2025 as against Rs 8.47 crore during the previous quarter ended September 2024. Sales rose 23.35% to Rs 111.05 crore in the quarter ended September 2025 as against Rs 90.03 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales111.0590.03 23 OPM %22.8321.84 - PBDT23.4117.18 36 PBT18.4512.55 47 NP14.128.47 67 Powered by Capital Market - Live News

Kwality Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live News

Kwality Pharmaceuticals announced that the Annual General Meeting(AGM) of the company will be held on 9 September 2025.Powered by Capital Market - Live News

Kwality Pharmaceutical has received registration for Bleomycin 15 IU in Mexico for sale and distribution. Bleomycin is a widely used anti-cancer medicine, effective in the treatment of Hodgkin`s lymphoma, testicular cancer, and certain squamous cell carcinomas. The company said, This approval further strengthens our expansion into highly regulated markets, reinforcing our commitment to delivering quality oncology products globally.The projected business potential is around 1 million USD in the first year, and supplies will commence before the end of Q2FY26Powered by Capital Market - Live News

Net profit of Kwality Pharmaceuticals rose 42.70% to Rs 11.93 crore in the quarter ended June 2025 as against Rs 8.36 crore during the previous quarter ended June 2024. Sales rose 39.21% to Rs 111.48 crore in the quarter ended June 2025 as against Rs 80.08 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales111.4880.08 39 OPM %21.6821.65 - PBDT21.7915.14 44 PBT17.0311.12 53 NP11.938.36 43 Powered by Capital Market - Live News